Supernus Pharmaceuticals (SUPN) Non-Current Debt (2011 - 2021)
Supernus Pharmaceuticals (SUPN) posted quarterly Non-Current Debt of $379.3 million for Q4 2021, up 4655.51% on a QoQ basis from $8.0 million in Q1 2013.
Supernus Pharmaceuticals (SUPN) Non-Current Debt (2011 - 2021) Analysis & Trends
Supernus Pharmaceuticals has reported Non-Current Debt for 4 years, with the latest figure at $379.3 million in Q4 2021.
- Non-Current Debt for Q4 2021 came in at $379.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $379.3 million (changed N/A YoY), and the FY2021 annual result was $379.3 million, changed N/A from the prior year.
- Non-Current Debt rose to $379.3 million in Q4 2021, from $8.0 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $379.3 million in Q4 2021 and troughed at $379.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 379.25 Mn |
| Mar 31, 2013 | 7.98 Mn |
| Dec 31, 2012 | 11.09 Mn |
| Sep 30, 2012 | 14.12 Mn |
| Jun 30, 2012 | 17.06 Mn |
| Mar 31, 2012 | 19.93 Mn |
| Dec 31, 2011 | 22.71 Mn |